中文摘要：本发明提供了一种可预防和治疗肺炎链球菌相关疾病的制剂及其方法；特别是一种由肺炎球菌表面抗原蛋白A（Psa A）组成的重组脂化融合蛋白；该融合蛋白从N端到C端分别为PsaA天然脂质信号肽、PsaA功能性基因。本发明同时提供了由该融合蛋白制成的疫苗，该疫苗能够诱导抗肺炎链球菌的广谱粘膜免疫反应。
外文摘要：There are provided compositions and methods for prevention or treatment of Streptococcus pneumoniae (SP)-associated diseases. More specifically, there are provided recombinant lipidated fusion proteins comprising pneumococcal surface antigen A (PsaA), the recombinant lipidated fusion proteins comprising, from N-terminus to C-terminus, the N-terminal native lipid signal peptide of PsaA and the C-terminal structural gene for PsaA. Methods of inducing broad spectrum mucosal immunity against SP comprising administering a vaccine comprising recombinant lipidated fusion proteins are also described.
NOVELTY - A recombinant lipidated fusion protein comprising pneumococcal surface antigen A (PsaA) is new, where the recombinant lipidated fusion protein comprises N-terminal native lipid signal peptide of PsaA and C-terminal structural gene for PsaA from N-terminus to C-terminus.
USE - The recombinant lipidated fusion protein is useful in composition for preventing or treating an S.pneumoniae associated disease, or inducing mucosal immunity against S.pneumoniae infection or associated disease in a subject by inducing T-helper 1 response and production of secretory immunoglobulin A (IgA) in subject. The S.pneumoniae associated disease is pneumonia, meningitidis, ear infection, sinus infection, or bacteremia (all claimed). The subject is human.
ADVANTAGE - The recombinant lipidated fusion protein treats disease without adverse side effects, a nd increases specificity and/or reduces cross-reactivity of induced immune response, and is produced in a simple and cost-effective manner.
主权项：INDEPENDENT CLAIMS are included for the following: (1) method (M1) of producing recombinant lipidated fusion protein; (2) composition (C1) comprising above-mentioned recombinant lipidated fusion protein, and diluent, carrier, or excipient; (3) vaccine comprising recombinant lipidated fusion protein, and an adjuvant; (4) isolated antibody or its fragment specific for recombinant lipidated fusion protein, or recombinant lipidated fusion protein produced by the above-mentioned method; (4) composition (C2) comprising isolated antibody or its fragment, and diluent, carrier, or excipient; (5) method for preventing or treating an Streptococcus pneumoniae (SP)-associated disease, involves administering the above-mentioned composition to subject; and ( 6) method (M2) for inducing immunity against S.pneumoni ae infec tion in a subject, involves administering composition, vaccine, or antibody or their fragments to the subject.
申请号：WO2016CA51449
公开/公告号：WO2017096486A1
申请日：2016-12-09
公开/公告日：2017-06-15
申请/专利权人：NAT RES COUNCIL CANADA (CANA-C); NAT HEALTH RES INST (NAHE-C)
发明/设计人：LENG, C;CHEN, W;CHONG, P
分类号：A61K39/092; C07K14/315; C07K16/12; C07K7/08; C12N15/63; C12P21/02; A61K2039/6018 Application number: WO2016CA51449 20161209
主分类号：A61K39/09; A61P31/04; A61P37/04; C07K14/315; C07K16/12; C07K7/08; C12N15/31; C12N15/63; C12P21/02
点击下载：一种脂化肺炎链球菌的组成、制备方法及应用